Recently, the Ministry of industry and information technology announced the list of the fourth batch of national specialized and special new "small giant" enterprises. Relying on its development and accumulation in the field of molecular diagnosis for many years, Uni-medica was successfully selected as the fourth batch of national specialized and special new "small giant" enterprises
This selection of "small giant" enterprises specializing in specialty and special innovation not only highly recognizes the technological innovation, product market share and progressiveness management of Uni-medica Research and development, but also puts forward higher requirements for the future development of Uni-medica.
As a pioneer enterprise in the intelligent diagnosis of infection and maternal and child multi omics, Uni-medica will actively play the exemplary role of "small giant" enterprises in small and medium-sized enterprises, continue to promote technological innovation, continue to popularize high-quality diagnostic technology, continue to create value for life and health, and become a leader in precision prevention.
About specialization and innovation
About Allied Medicine
Shenzhen Uni-medica Technology Co., LTD. (Uni-Medica for short) is located in Nanshan District of Shenzhen City. It is a national high-tech enterprise, committed to the development of integrated solutions of in vitro diagnostic reagents and instruments, and has carried out a series of scientific research cooperation with many scientific research institutions such as Hong Kong University of Science and Technology, Shenzhen University and Chinese Academy of Sciences. It has undertaken a number of national and provincial science and technology projects, received investment from Xiantong Capital and Shenzhen Science and Technology Financial Service Center, and was selected as one of the top 100 innovative enterprises in China.
Uni-medica focuses on the research and development and industrialization of innovative products in the fields of infectious diseases and reproductive health. It has multiple technology platforms, such as fluorescence quantitative PCR platform, high-throughput sequencing platform, flow cytometry platform, immunofluorescence microscopy imaging platform, and mature and complete medical device production registration system. Based on multi-omics detection technology, it provides a complete solution for accurate diagnosis of infectious diseases and reproductive health.
.png)
.jpg)
.jpg)
